Perianal Crohn Fistula: Coordinated Surgical and Medical Care

Perform pelvic MRI before any operative intervention in suspected complex perianal Crohn fistula. Use a dedicated protocol with T2-weighted and post-contrast T1 sequences in axial, coronal, and sagittal planes.

Document the tract relative to the sphincter complex using the Parks anatomical scheme and apply Van Assche grading or the simpler St James scale on MRI reports to support clinical communication.

Distinguish simple from complex perianal Crohn fistula on MRI. Simple disease is low (superficial, low intersphincteric, or low transsphincteric), with a single external opening and no secondary tracts, abscess, proctitis, or stricture.

Evaluate for proctitis and anorectal stricture on the same MRI study, since both upgrade an apparently simple fistula to complex disease and alter the medical regimen and surgical timing.

Repeat pelvic MRI at 6 to 12 months after initiating combined therapy to assess radiologic healing. Clinical closure of the external opening alone is an unreliable marker of true tract resolution.

Consider endoanal ultrasound as an adjunct when MRI is contraindicated, equivocal, or unavailable, particularly when intraoperative mapping is needed in a hands-on setting.

Perform EUA with a colorectal surgeon experienced in inflammatory bowel disease whenever the MRI reveals complex anatomy, an abscess, or proctitis.

Drain every collection identified on imaging or palpation at the index operation. Untreated sepsis is the single most common reason that subsequent biologic therapy appears to fail.

Place a loose, non-cutting seton (vessel loop or silastic) through every complex tract. The seton maintains drainage, prevents recurrent abscess, and allows biologic therapy to work without trapping pus.

Do not use cutting setons in perianal Crohn fistula. The risk of permanent faecal incontinence outweighs any potential closure benefit in an inflammatory disease that already threatens the sphincter.

Avoid primary fistulotomy in high transsphincteric, suprasphincteric, or anterior tracts in women. Reserve fistulotomy for selected low, simple tracts with no proctitis after multidisciplinary discussion.

Leave the seton in place until clinical response is established — defined as cessation of drainage on examination and a closed, non-tender external opening, not by a fixed calendar.

Time seton removal to coincide with biologic induction. Removing the seton around the second or third induction dose, when local inflammation is settling, balances closure against the risk of premature occlusion and re-collection.

Consider definitive closure procedures (ligation of intersphincteric fistula tract or endorectal advancement flap) only after at least 6 months of biologic therapy, with documented absence of proctitis and radiologic healing.

Start infliximab 5 mg/kg IV at weeks 0, 2, and 6, then every 8 weeks for maintenance, in symptomatic perianal Crohn fistula once sepsis is drained. Infliximab has the largest randomised evidence base of any biologic in fistulizing disease.

Consider intensified induction (10 mg/kg, or shortened intervals) in patients with extensive complex disease, low serum albumin, or high body weight — all predictors of accelerated drug clearance.

Combine infliximab with an immunomodulator (azathioprine 2–2.5 mg/kg or 6-mercaptopurine) where feasible. Combination therapy improves trough levels, reduces immunogenicity, and improves fistula response over monotherapy.

Check thiopurine methyltransferase activity or genotype before starting azathioprine or 6-mercaptopurine to identify patients at risk of severe myelosuppression.

Use therapeutic drug monitoring to target higher infliximab trough levels in perianal Crohn fistula than in luminal disease — typically above 10–15 mcg/mL during induction and at least 7–10 mcg/mL during maintenance, based on observational evidence.

Use adalimumab as an alternative anti-TNF (160 mg week 0, 80 mg week 2, then 40 mg every 2 weeks) when infliximab is unsuitable. Efficacy in fistulizing disease is supported by post-hoc analyses of CHARM and subsequent cohorts.

Consider ustekinumab or vedolizumab in patients who have lost response to or are intolerant of anti-TNF therapy, recognising that evidence specifically for fistula closure is less robust than for luminal disease.

Consider local injection of allogeneic adipose-derived mesenchymal stem cells (darvadstrocel) in complex perianal Crohn fistula refractory to conventional therapy with adequately drained, single or multi-tract disease.

Prescribe ciprofloxacin or metronidazole as adjunctive antibiotic therapy during the induction phase to reduce drainage and discomfort, recognising that antibiotics alone do not heal the fistula.

Manage every patient with complex perianal Crohn fistula in a multidisciplinary clinic that includes a colorectal surgeon and an IBD gastroenterologist. Coordinated decision-making improves response rates and reduces unnecessary operations.

Treat coexisting proctitis aggressively with biologic and immunomodulator therapy. Closure of perianal Crohn fistula will not be achieved while the rectal mucosa remains inflamed.

Continue maintenance biologic therapy indefinitely in patients with healed perianal Crohn fistula. Stopping is associated with high relapse rates and the relapsed disease is often more aggressive than at presentation.

Reserve faecal diversion (loop ileostomy) for severe refractory disease, life-threatening sepsis, or as a bridge to organ-preserving therapy in a multidisciplinary setting. Diversion alone rarely cures perianal Crohn fistula.

Counsel patients that proctectomy with permanent stoma may be necessary in destroyed sphincter anatomy, intractable disease, or anorectal cancer, and frame it as a definitive treatment when reconstruction has failed.

Reassess clinically at 8 and 14 weeks after starting biologic therapy. Use the Fistula Drainage Assessment — cessation of drainage on gentle compression at two consecutive visits defines clinical response.

Obtain a follow-up pelvic MRI between 6 and 12 months after biologic initiation to assess radiologic healing, even when the patient is asymptomatic and the external opening appears closed.

Aim for deep remission — clinical, biochemical, and radiologic healing — before contemplating any definitive closure procedure or de-escalation of medical therapy.

Counsel patients about the long-term risk of anorectal cancer in chronic perianal Crohn fistula. Examine any non-healing or atypical tract with biopsy, particularly when behaviour changes after years of stable disease.

Document the goals of care explicitly with every patient. For most, the realistic goal is durable symptomatic control and sphincter preservation, not anatomical cure.